Quantcast

Latest Neuraminidase inhibitors Stories

2009-09-21 06:30:00

BIRMINGHAM, Ala., Sept. 21 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has been awarded a $77.2 million contract modification by the U.S. Department of Health & Human Services (HHS) to complete Phase 3 development of its influenza neuraminidase inhibitor, intravenous (i.v.) peramivir, for the treatment of complicated influenza. "We are very excited to continue working with the U.S. government to advance the development of...

cdaee1855df39e27df826c5f74dce8321
2009-09-14 11:20:00

Researchers reported on Sunday a new experimental flu drug that can stop the swine flu virus from infecting cells and it even seems capable of keeping it from mutating into drug-resistant forms. After performing tests on mice and in lab dishes, they saw that NexBio Inc.'s drug Fludase can stop the seasonal influenza virus from infecting cells while fighting certain strains of the virus that have become resistant to Roche AG's popular influenza drug Tamiflu, the company said. "Extensive,...

2009-09-13 13:15:00

SAN FRANCISCO, Sept. 13 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that two new observational studies concluded that influenza patients treated with Tamiflu(R) (oseltamivir phosphate) had significantly higher survival rates than untreated patients. The studies, examining nearly 1,000 people, analyzed outcomes for two different groups -adults and children diagnosed with the highly pathogenic A (H5N1) avian influenza and adults hospitalized with seasonal influenza....

2009-09-13 12:45:00

SAN FRANCISCO, Sept. 13 /PRNewswire/ -- Adamas Pharmaceuticals, Inc., a privately held company, announced today that a multi-center in vitro study of its proprietary triple combination antiviral drug (TCAD) therapy showed substantially greater potency against seasonal and novel H1N1 influenza viruses than currently recommended single or double therapy and that the triple combination is active against drug-resistant flu strains. The study was presented during an oral presentation at the...

2009-09-10 12:57:33

Treating people with H1N1 flu with anti-virals oseltamivir and zanamivir should only be considered for those at high risk of complications, U.S. officials say. The Centers for Disease Control and Prevention's Mortality and Morbidity Weekly Report released Thursday says oseltamivir resistance was found in pandemic H1N1 virus from two patients who developed influenza while taking oseltamivir. The patients attended a summer camp in North Carolina where oseltamivir was given to most campers and...

2009-09-09 17:29:00

SAN FRANCISCO, Sept. 9 /PRNewswire-USNewswire/ -- Blue Shield of California announced today that it will cover the administrative costs of the H1N1 virus (swine flu) vaccine for all its members, regardless of which plan they have. Blue Shield will be waiving prior authorizations, copays and deductibles for office visits when members go to an in-network doctor to get H1N1 vaccinations. The U.S. Government will be providing H1N1 vaccinations (including the equipment, like syringes) free...

2009-09-08 12:51:00

LOURES, Portugal, September 8 /PRNewswire/ -- Hovione is pleased to announce that its TwinCaps(R) inhaler licensees Daiichi Sankyo Co. Ltd. (Tokyo, Japan) and Biota Holdings Ltd (Victoria, Australia) have both announced successful Phase III trials for CS-8958, a new long-acting neuraminidase inhibitor for treatment of influenza (known as a prodrug of laninamivir). CS-8958, co-owned by Daiichi Sankyo and Biota, is delivered by TwinCaps(R), a patented dry powder inhaler which Hovione...

2009-09-03 12:00:00

EMERYVILLE, Calif., Sept. 3 /PRNewswire/ -- Adamas Pharmaceuticals, Inc., a privately held company, announced today that new research data will be delivered as an oral presentation during the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, CA on September 13, 2009. The presentation will describe results from a multi-institutional collaborative in vitro study of Adamas' triple combination antiviral drug (TCAD) therapy. Presentation...

2009-08-25 09:30:00

EMERYVILLE, Calif., Aug. 25 /PRNewswire/ -- Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has expanded its management team, naming Michael D. Coffee, Senior Vice President, Sales and Marketing, and Amy K. Patick, PhD, Vice President, Research. Mr. Coffee will report to Gregory Went, PhD, Chief Executive Officer and Chairman of Adamas and will be responsible for US sales and marketing, identification of ex-US partners and new product initiatives. His...

f90af40106e61e35403788262ce716ff1
2009-08-24 06:25:00

British researchers reported on Friday that the flu drugs Tamiflu and Relenza might not be worthwhile to treat seasonal influenza in healthy adults. "Recommending the use of antiviral drugs for the treatment of people presenting with symptoms is unlikely to be the most appropriate course of action," wrote Jane Burch of the University of York and colleagues. Their findings support an advisory from the World Health Organization (WHO) that says healthy patients who get H1N1 swine flu without...


Word of the Day
penuche
  • A fudgelike confection of brown sugar, cream or milk, and chopped nuts.
'Penuche' is a variant of 'panocha,' a coarse grade of sugar made in Mexico. 'Panocha' probably comes from the Spanish 'panoja, panocha,' ear of grain.
Related